Form 4: Zoetis Director Broadhurst Receives Equity Grant

Zoetis Inc. Director Vanessa Broadhurst reported the acquisition and vesting of restricted stock units, increasing her beneficial ownership.

Summary

• Vanessa Broadhurst, a Director of Zoetis Inc. (ZTS), reported changes in her beneficial ownership of company stock.
• On February 18, 2026, she was granted 1,936 Restricted Stock Units (RSUs), which vested and were settled into shares of Zoetis common stock on the same day.
• These RSUs were issued under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
• Additionally, 1,619.3325 RSUs, which vested and were settled into shares of Zoetis common stock on February 19, 2025, are also reported as beneficially owned.
• Each RSU represents a contingent right to receive one share of Zoetis Inc. common stock, subject to continued service through the vesting date.
• Following the reported transactions, Broadhurst beneficially owns 1,936 derivative securities (RSUs) from the 2026 event and 1,619.3325 derivative securities (RSUs) from the 2025 event.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine disclosure of director compensation, which is neither inherently positive nor negative for the company's immediate operational or financial performance.

Positives

• The grant of equity to a director aligns their interests with those of shareholders, promoting long-term value creation.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the standard vesting conditions for equity awards.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in corporate governance, aligning director interests with shareholder value. This is common across the pharmaceutical and animal health sectors, where long-term incentives are used to retain and motivate key personnel.

Comparison to Industry Standards

• Equity compensation for directors, often in the form of restricted stock units, is a standard practice across industries, including the animal health and pharmaceutical sectors.
• Companies such as Elanco Animal Health (ELAN) and IDEXX Laboratories (IDXX) also utilize similar equity awards for their non-employee directors, typically with vesting schedules designed to encourage long-term commitment and performance.
• The specific number of units granted is generally determined by the company's compensation philosophy, stock price, and the director's role and responsibilities, making this grant consistent with broader industry norms for director remuneration.

Corporate Governance

Related Party Transactions

• Grant of Restricted Stock Units to Director Vanessa Broadhurst as part of her compensation package, which is a standard related-party transaction for director remuneration.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information that would significantly alter the investment thesis for Zoetis Inc. It reflects ongoing corporate governance and compensation structures rather than a material operational or financial event, thus warranting a 'hold' recommendation.

Keywords

Zoetis, ZTS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership